-
Annual General Meeting
Nuclear Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was recorded as a recent event.
-
Balance Sheet
The activity Nuclear Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Pune. was completed.
-
Director Appointment
Priyanka Ganpatarav Pachunde was appointed as a Director was appointed as a Director on 27 Feb 2017 & has been associated with this company since 8 years 10 months . was recorded as a recent event.
-
Director Appointment
Satish Ganpati Chavan was appointed as a Director was appointed as a Director on 27 Feb 2017 & has been associated with this company since 8 years 10 months . was recorded as a recent event.
-
Company Incorporation
Nuclear Pharmaceuticals Private Limited was registered on 27 Feb 2017 with Roc Pune & aged 8 years 10 months as per MCA records. was recorded as a recent event.
Nuclear Pharmaceuticals Private Limited - Company Profile
Nuclear Pharmaceuticals Private Limited, a active private limited company, was established on 27 February 2017 in Sangliwadi, Maharashtra, India. Engaging in specialty within the trading sector, it holds CIN: U51909PN2017PTC169111. Registered under ROC Roc Pune. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹0.26 M.
It upholds a compliant status. Its leadership includes Priyanka Ganpatarav Pachunde (Director), Satish Ganpati Chavan (Director). Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at C/O Satish Ganpati Chavan, S.No.269/1A/2,Magadum Plot,Islampur Road, Sangliwadi, Maharashtra, 416416.
Company Details
- CIN/LLPIN
U51909PN2017PTC169111
- Registration Number
169111
- Incorporation Date
27 February 2017
- Authorized Capital
₹1.00 M
- Paid-Up Capital
₹0.26 M
- ROC Code
Roc Pune
-
Listing Status
Unlisted
- Company Status
Active
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.26 M
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2025
- Revenue Growth 101.75%
- Profit Growth -47.12%
- Ebitda 178.96%
- Net Worth 11.81%
- Total Assets 9.73%
Nuclear Pharmaceuticals Private Limited
Company Report FY 2025-2026Comprehensive Company Insights
Explore comprehensive insights into Nuclear Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Priyanka Ganpatarav Pachunde | Director | 27 Feb 2017 | Current |
| Satish Ganpati Chavan | Director | 27 Feb 2017 | Current |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nuclear Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 101.75% increase. The company also saw a substantial fall in profitability, with a 47.12% decrease in profit. The company's net worth Soared by an impressive increase of 11.81%.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
******* |
******* |
******* |
******* |
||
| Revenue from Operations |
|
******* |
******* |
******* |
******* |
||
| Total Assets |
|
******* |
******* |
******* |
******* |
||
| Profit or Loss |
|
*******
|
*******
|
*******
|
*******
|
||
| Net Worth |
|
*******
|
*******
|
*******
|
*******
|
||
| EBITDA |
|
******* |
******* |
******* |
******* |
Unlock access to Nuclear Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
-
Promoters: 92.83%
-
Public: 4.10%
-
Others: 3.07%
| FY (2024) | FY (2023) | FY (2022) | FY (2021) | FY (2020) | |
|---|---|---|---|---|---|
| Promoters | 92.83 | 94.62 | 94.55 | 94.55 | 94.55 |
| Public | 4.10 | 3.89 | 3.95 | 3.96 | 3.98 |
| Others | 3.07 | 1.49 | 1.50 | 1.49 | 1.47 |
Reveal ownership structures and financial performance - Get instant access now!
Unlock and access historical data on people associated with Nuclear Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
| Employee Date | Number of Employees |
|---|---|
| 2020 | 78,000 |
| 2021 | 80,500 |
| 2022 | 83,200 |
| 2023 | 86,000 |
| 2024 | 89,500 |
| 2025 | 92,000 |
Gain comprehensive insights into the Deals and Valuation data of Nuclear Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nuclear Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
What is the CIN of Nuclear Pharmaceuticals Private Limited?
The CIN of Nuclear Pharmaceuticals Private Limited is U51909PN2017PTC169111.
Where is Nuclear Pharmaceuticals Private Limited headquartered?
Nuclear Pharmaceuticals Private Limited is headquartered at C/O Satish Ganpati Chavan, S.No.269/1A/2,Magadum Plot,Islampur Road, Sangliwadi, Maharashtra, 416416.
When was Nuclear Pharmaceuticals Private Limited incorporated?
Nuclear Pharmaceuticals Private Limited was incorporated on 27 February 2017.
Who are the current directors of Nuclear Pharmaceuticals Private Limited?
The current directors of Nuclear Pharmaceuticals Private Limited are
What is the primary industry of Nuclear Pharmaceuticals Private Limited?
The primary industry of Nuclear Pharmaceuticals Private Limited is Trading.
Is Nuclear Pharmaceuticals Private Limited a listed company?
Nuclear Pharmaceuticals Private Limited is unlisted.
What is the capital structure of Nuclear Pharmaceuticals Private Limited?
The authorized capital of Nuclear Pharmaceuticals Private Limited is ₹1.00 M, and the paid-up capital is ₹0.26 M.
What is the compliance status of Nuclear Pharmaceuticals Private Limited?
The compliance status of Nuclear Pharmaceuticals Private Limited is Compliant.
+91-XXXXXXXXXX